Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
313 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hypersensitivity - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Hypersensitivity - Pipeline Review, H2 2016', provides an overview of the Hypersensitivity pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hypersensitivity - The report reviews pipeline therapeutics for Hypersensitivity by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hypersensitivity therapeutics and enlists all their major and minor projects - The report assesses Hypersensitivity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hypersensitivity Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hypersensitivity - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Hypersensitivity Overview 7 Therapeutics Development 8 Hypersensitivity - Therapeutics under Development by Companies 10 Hypersensitivity - Therapeutics under Investigation by Universities/Institutes 16 Hypersensitivity - Pipeline Products Glance 17 Hypersensitivity - Products under Development by Companies 21 Hypersensitivity - Products under Investigation by Universities/Institutes 30 Hypersensitivity - Companies Involved in Therapeutics Development 31 Hypersensitivity - Therapeutics Assessment 88 Drug Profiles 100 Hypersensitivity - Dormant Projects 272 Hypersensitivity - Discontinued Products 283 Hypersensitivity - Product Development Milestones 284 Appendix 297
List of Tables
Number of Products under Development for Hypersensitivity, H2 2016 23 Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016 24 Number of Products under Development by Companies, H2 2016 26 Number of Products under Development by Companies, H2 2016 (Contd..1) 27 Number of Products under Development by Companies, H2 2016 (Contd..2) 28 Number of Products under Development by Companies, H2 2016 (Contd..3) 29 Number of Products under Development by Companies, H2 2016 (Contd..4) 30 Number of Products under Investigation by Universities/Institutes, H2 2016 31 Comparative Analysis by Late Stage Development, H2 2016 32 Comparative Analysis by Clinical Stage Development, H2 2016 33 Comparative Analysis by Early Stage Development, H2 2016 34 Comparative Analysis by Unknown Stage Development, H2 2016 35 Products under Development by Companies, H2 2016 36 Products under Development by Companies, H2 2016 (Contd..1) 37 Products under Development by Companies, H2 2016 (Contd..2) 38 Products under Development by Companies, H2 2016 (Contd..3) 39 Products under Development by Companies, H2 2016 (Contd..4) 40 Products under Development by Companies, H2 2016 (Contd..5) 41 Products under Development by Companies, H2 2016 (Contd..6) 42 Products under Development by Companies, H2 2016 (Contd..7) 43 Products under Development by Companies, H2 2016 (Contd..8) 44 Products under Investigation by Universities/Institutes, H2 2016 45 Hypersensitivity - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016 46 Hypersensitivity - Pipeline by Adverum Biotechnologies, Inc., H2 2016 47 Hypersensitivity - Pipeline by Aimmune Therapeutics, Inc., H2 2016 48 Hypersensitivity - Pipeline by Alfacyte Ltd, H2 2016 49 Hypersensitivity - Pipeline by ALK-Abello A/S, H2 2016 50 Hypersensitivity - Pipeline by Allakos Inc., H2 2016 51 Hypersensitivity - Pipeline by Allergopharma GmbH & Co. KG, H2 2016 52 Hypersensitivity - Pipeline by Allergy Therapeutics Plc, H2 2016 53 Hypersensitivity - Pipeline by Amgen Inc., H2 2016 54 Hypersensitivity - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 55 Hypersensitivity - Pipeline by AnaptysBio, Inc., H2 2016 56 Hypersensitivity - Pipeline by Anergis SA, H2 2016 57 Hypersensitivity - Pipeline by Antigen Express, Inc., H2 2016 58 Hypersensitivity - Pipeline by Aravax Pty Ltd, H2 2016 59 Hypersensitivity - Pipeline by Array BioPharma Inc., H2 2016 60 Hypersensitivity - Pipeline by ASIT biotech s.a., H2 2016 61 Hypersensitivity - Pipeline by AskAt Inc., H2 2016 62 Hypersensitivity - Pipeline by Astellas Pharma Inc., H2 2016 63 Hypersensitivity - Pipeline by BioLingus AG, H2 2016 64 Hypersensitivity - Pipeline by Biomay AG, H2 2016 65 Hypersensitivity - Pipeline by Biotec Pharmacon ASA, H2 2016 66 Hypersensitivity - Pipeline by Boehringer Ingelheim GmbH, H2 2016 67 Hypersensitivity - Pipeline by Circassia Pharmaceuticals Plc, H2 2016 68 Hypersensitivity - Pipeline by DBV Technologies S.A., H2 2016 69 Hypersensitivity - Pipeline by DNJ Pharma, Inc., H2 2016 70 Hypersensitivity - Pipeline by EA Pharma Co Ltd, H2 2016 71 Hypersensitivity - Pipeline by Enzene Biosciences Ltd., H2 2016 72 Hypersensitivity - Pipeline by EpiVax, Inc., H2 2016 73 Hypersensitivity - Pipeline by Fountain Biopharma Inc., H2 2016 74 Hypersensitivity - Pipeline by HAL Allergy BV, H2 2016 75 Hypersensitivity - Pipeline by iCeutica, Inc., H2 2016 76 Hypersensitivity - Pipeline by ImmunoFrontier, Inc., H2 2016 77 Hypersensitivity - Pipeline by Immunomic Therapeutics, Inc., H2 2016 78 Hypersensitivity - Pipeline by Immupharma Plc, H2 2016 79 Hypersensitivity - Pipeline by InMed Pharmaceuticals Inc., H2 2016 80 Hypersensitivity - Pipeline by Interprotein Corporation, H2 2016 81 Hypersensitivity - Pipeline by Japan Tobacco Inc., H2 2016 82 Hypersensitivity - Pipeline by JW Pharmaceutical Corporation, H2 2016 83 Hypersensitivity - Pipeline by Laboratorios LETI S.L., H2 2016 84 Hypersensitivity - Pipeline by Monosol Rx, LLC, H2 2016 85 Hypersensitivity - Pipeline by NAL Pharmaceuticals Ltd., H2 2016 86 Hypersensitivity - Pipeline by Neovacs SA, H2 2016 87 Hypersensitivity - Pipeline by Novartis AG, H2 2016 88 Hypersensitivity - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 89 Hypersensitivity - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 90 Hypersensitivity - Pipeline by REGiMMUNE Corporation, H2 2016 91 Hypersensitivity - Pipeline by Roxall Medizin GmbH, H2 2016 92 Hypersensitivity - Pipeline by Sanofi, H2 2016 93 Hypersensitivity - Pipeline by Sealife PHARMA GMBH, H2 2016 94 Hypersensitivity - Pipeline by Stallergenes Greer plc, H2 2016 95 Hypersensitivity - Pipeline by Stallergenes SAS, H2 2016 96 Hypersensitivity - Pipeline by Swecure AB, H2 2016 97 Hypersensitivity - Pipeline by Therabron Therapeutics, Inc., H2 2016 98 Hypersensitivity - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016 99 Hypersensitivity - Pipeline by Toleranzia AB, H2 2016 100 Hypersensitivity - Pipeline by United Biomedical, Inc., H2 2016 101 Hypersensitivity - Pipeline by United BioPharma, Inc., H2 2016 102 Assessment by Monotherapy Products, H2 2016 103 Assessment by Combination Products, H2 2016 104 Number of Products by Stage and Target, H2 2016 106 Number of Products by Stage and Mechanism of Action, H2 2016 109 Number of Products by Stage and Route of Administration, H2 2016 112 Number of Products by Stage and Molecule Type, H2 2016 114 Hypersensitivity - Dormant Projects, H2 2016 287 Hypersensitivity - Dormant Projects (Contd..1), H2 2016 288 Hypersensitivity - Dormant Projects (Contd..2), H2 2016 289 Hypersensitivity - Dormant Projects (Contd..3), H2 2016 290 Hypersensitivity - Dormant Projects (Contd..4), H2 2016 291 Hypersensitivity - Dormant Projects (Contd..5), H2 2016 292 Hypersensitivity - Dormant Projects (Contd..6), H2 2016 293 Hypersensitivity - Dormant Projects (Contd..7), H2 2016 294 Hypersensitivity - Dormant Projects (Contd..8), H2 2016 295 Hypersensitivity - Dormant Projects (Contd..9), H2 2016 296 Hypersensitivity - Dormant Projects (Contd..10), H2 2016 297 Hypersensitivity - Discontinued Products, H2 2016 298
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
